OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!
If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.
Requested Article:
Therapeutic drug monitoring of biopharmaceuticals in inflammatory rheumatic and musculoskeletal disease: a systematic literature review informing EULAR points to consider
C. Krieckaert, Borja Hernández‐Breijo, Johanna Elin Gehin, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002216-e002216
Open Access | Times Cited: 14
C. Krieckaert, Borja Hernández‐Breijo, Johanna Elin Gehin, et al.
RMD Open (2022) Vol. 8, Iss. 2, pp. e002216-e002216
Open Access | Times Cited: 14
Showing 14 citing articles:
High-throughput, low-cost quantification of 11 therapeutic antibodies using caprylic acid precipitation and LC-MS/MS
Erik I. Hallin, Trond Trætteberg Serkland, Tormod Bjånes, et al.
Analytica Chimica Acta (2024) Vol. 1313, pp. 342789-342789
Open Access | Times Cited: 7
Erik I. Hallin, Trond Trætteberg Serkland, Tormod Bjånes, et al.
Analytica Chimica Acta (2024) Vol. 1313, pp. 342789-342789
Open Access | Times Cited: 7
Therapeutic Drug Monitoring of Biologics: Current Practice, Challenges and Opportunities – a Workshop Report
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Sophie Shubow, Michele Gunsior, Amy S. Rosenberg, et al.
The AAPS Journal (2025) Vol. 27, Iss. 2
Closed Access
Assessing Immunogenicity of Biologic Drugs in Inflammatory Joint Diseases: Progress Towards Personalized Medicine
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Johanna Elin Gehin, Guro Løvik Goll, Marthe Kirkesæther Brun, et al.
BioDrugs (2022) Vol. 36, Iss. 6, pp. 731-748
Open Access | Times Cited: 23
Adalimumab serum levels and anti-drug antibodies: associations to treatment response and drug survival in inflammatory joint diseases
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Ingrid Jyssum, Johanna Elin Gehin, Joseph Sexton, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 6, pp. 1746-1755
Open Access | Times Cited: 9
Proactive therapeutic drug monitoring of biologic drugs in adult patients with inflammatory bowel disease, inflammatory arthritis, or psoriasis: a clinical practice guideline
Letícia Kawano-Dourado, Eirik Klami Kristianslund, Dena Zeraatkar, et al.
BMJ (2024), pp. e079830-e079830
Closed Access | Times Cited: 2
Letícia Kawano-Dourado, Eirik Klami Kristianslund, Dena Zeraatkar, et al.
BMJ (2024), pp. e079830-e079830
Closed Access | Times Cited: 2
Perspectives of Therapeutic Drug Monitoring of Biological Agents in Non-Infectious Uveitis Treatment: A Review
Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 766-766
Open Access | Times Cited: 6
Manuel Busto-Iglesias, Lorena Rodríguez-Martínez, Carmen Antía Rodríguez-Fernández, et al.
Pharmaceutics (2023) Vol. 15, Iss. 3, pp. 766-766
Open Access | Times Cited: 6
Overcoming provider barriers to therapeutic drug monitoring of tumour necrosis factor inhibitors for rheumatoid arthritis: a qualitative analysis
Sean P. Gavan, Katherine Payne, Anne Barton
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 1
Sean P. Gavan, Katherine Payne, Anne Barton
Rheumatology Advances in Practice (2024) Vol. 8, Iss. 2
Open Access | Times Cited: 1
Clinical pharmacokinetics and pharmacodynamics of oral systemic nonbiologic therapies for psoriasis patients
Justin M. Eichinger, Divya M. Shan, Jonathan D. Greenzaid, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 249-262
Closed Access | Times Cited: 1
Justin M. Eichinger, Divya M. Shan, Jonathan D. Greenzaid, et al.
Expert Opinion on Drug Metabolism & Toxicology (2024) Vol. 20, Iss. 4, pp. 249-262
Closed Access | Times Cited: 1
Prospective study to characterize adalimumab exposure in pediatric patients with rheumatic diseases
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, et al.
Pediatric Rheumatology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Tatjana Welzel, Klervi Golhen, Andrew Atkinson, et al.
Pediatric Rheumatology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 1
Therapeutic Drug Monitoring: A Tool to Optimize Treatment of Inflammatory Joint Diseases
Silje Watterdal Syversen, Johanna Elin Gehin, Guro Løvik Goll, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 667-669
Open Access | Times Cited: 3
Silje Watterdal Syversen, Johanna Elin Gehin, Guro Løvik Goll, et al.
Arthritis & Rheumatology (2023) Vol. 76, Iss. 5, pp. 667-669
Open Access | Times Cited: 3
Efficacy, safety, and cost-effectiveness of therapeutic drug monitoring (TDM) for TNF inhibitor therapy in rheumatic disease: A systematic review and meta-analysis
Wen‐Liang Dong, Xiaowen Hu, Caiying Wu, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 63, pp. 152302-152302
Closed Access | Times Cited: 2
Wen‐Liang Dong, Xiaowen Hu, Caiying Wu, et al.
Seminars in Arthritis and Rheumatism (2023) Vol. 63, pp. 152302-152302
Closed Access | Times Cited: 2
Therapeutic serum level for adalimumab in rheumatoid arthritis: explorative analyses of data from a randomised phase III trial
Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
RMD Open (2024) Vol. 10, Iss. 4, pp. e004888-e004888
Open Access
Johanna Elin Gehin, Rolf Anton Klaasen, Eirik Klami Kristianslund, et al.
RMD Open (2024) Vol. 10, Iss. 4, pp. e004888-e004888
Open Access
Therapeutic drug monitoring of disease-modifying antirheumatic drugs in circulating leukocytes in immune-mediated inflammatory diseases
Dao-Hai Cheng, Zhenguang Huang
Inflammopharmacology (2023) Vol. 31, Iss. 4, pp. 1789-1811
Closed Access | Times Cited: 1
Dao-Hai Cheng, Zhenguang Huang
Inflammopharmacology (2023) Vol. 31, Iss. 4, pp. 1789-1811
Closed Access | Times Cited: 1
Non-trough serum drug levels of adalimumab and etanercept are associated with response in patients with psoriatic arthritis
Philippa D. K. Curry, Ryan Hum, Andrew P. Morris, et al.
Lara D. Veeken (2023) Vol. 64, Iss. 1, pp. 188-194
Open Access | Times Cited: 1
Philippa D. K. Curry, Ryan Hum, Andrew P. Morris, et al.
Lara D. Veeken (2023) Vol. 64, Iss. 1, pp. 188-194
Open Access | Times Cited: 1
Patterns and determinants of response to novel therapies in juvenile and adult-onset polyarthritis
Clément Triaille, Pierre Quartier, Lien De Somer, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 594-607
Open Access
Clément Triaille, Pierre Quartier, Lien De Somer, et al.
Lara D. Veeken (2023) Vol. 63, Iss. 3, pp. 594-607
Open Access
